Are Adaptogens Safe? Drug Interactions, Contraindications, and Quality Risks

London, United Kingdom — 31 March 2026

The assumption that adaptogens are inherently safe because they are "natural" is one of the most commercially dangerous misconceptions in the supplement industry. Most adaptogens do have favourable safety profiles in healthy adults at standard doses — but they are pharmacologically active compounds that interact with hormonal, neurological, and immune systems. For B2B buyers, formulators, and brand owners, understanding the real safety boundaries is essential for responsible product development and regulatory compliance.

Natural Does Not Mean Automatically Safe

The naturalistic fallacy — the belief that natural substances are inherently safer than synthetic ones — persists across consumer marketing despite having no pharmacological basis. Arsenic is natural. Hemlock is natural. The relevant question is not whether a compound comes from a plant but whether it has been studied at the doses being consumed, in the populations using it, and alongside the medications those populations may be taking.

Adaptogens are biologically active. Ashwagandha modulates cortisol and GABA receptors. Rhodiola influences serotonin and dopamine metabolism. Reishi suppresses inflammatory cytokines and modulates immune function. These are meaningful physiological interventions — precisely the reason they produce therapeutic effects — and they carry correspondingly meaningful interaction potential.

Drug Interactions: The Critical Concern

Thyroid medications: Ashwagandha has demonstrated thyroid-stimulating effects in multiple studies, increasing T3 and T4 levels in subclinical hypothyroid patients. For consumers already taking levothyroxine or other thyroid hormone replacement, concurrent ashwagandha use may potentiate thyroid hormone levels beyond the target range, potentially causing symptoms of hyperthyroidism. This is not a theoretical concern — case reports have documented clinically significant thyroid elevations in ashwagandha users on thyroid medication. B2B brands formulating with ashwagandha should include clear label warnings regarding thyroid conditions.

Antidepressants and anxiolytics: Rhodiola's mild MAO-inhibitory activity raises interaction potential with SSRIs, SNRIs, and tricyclic antidepressants. While clinically significant serotonin syndrome from rhodiola alone is unlikely at standard doses, the additive serotonergic effect in combination with pharmaceutical antidepressants warrants caution. Ashwagandha's GABAergic activity similarly raises theoretical interaction concerns with benzodiazepines and other GABA-modulating medications, potentially amplifying sedative effects.

Blood pressure medications: Several adaptogens, including ashwagandha and eleuthero, have demonstrated mild hypotensive effects. For consumers on antihypertensive medications, additive blood pressure reduction could result in symptomatic hypotension — dizziness, lightheadedness, or fainting. While the magnitude of adaptogen-induced blood pressure changes is typically modest (5–10 mmHg systolic), this may be clinically significant in consumers already titrated to a target blood pressure range.

Immunosuppressants: Reishi's immune-stimulating beta-glucans present a direct pharmacological conflict with immunosuppressive medications prescribed for autoimmune conditions, organ transplant recipients, or certain cancers. Upregulating natural killer cell activity and T-cell function — precisely reishi's therapeutic mechanism — is contraindicated in any patient whose treatment depends on immune suppression. This interaction is not subtle and should be treated as a hard contraindication in product labelling.

Pregnancy and Breastfeeding

The default clinical position on adaptogens during pregnancy and breastfeeding is cautious avoidance, and for good reason. Ashwagandha has demonstrated abortifacient effects in animal studies at high doses — while these doses exceed typical human supplementation, the margin of safety in pregnancy is rightly held to a higher standard. Rhodiola, reishi, and lion's mane lack sufficient human safety data in pregnant or lactating populations to support any confidence in their safety during these periods.

For B2B brands, this is non-negotiable from a regulatory and liability perspective. Products containing adaptogens should carry clear "not recommended during pregnancy or breastfeeding" statements. Attempting to market adaptogens as pregnancy-safe without clinical evidence exposes brands to significant legal and reputational risk.

Product Quality and Contamination

Beyond inherent pharmacological risks, product quality introduces an entirely separate layer of safety concern. Third-party testing of adaptogen supplements has repeatedly identified issues including:

Heavy metal contamination: Ashwagandha, as a root-based botanical, is particularly susceptible to heavy metal accumulation from soil (lead, arsenic, mercury, cadmium). Indian-sourced ashwagandha without adequate testing has been flagged in multiple UK and US regulatory actions. Reputable suppliers provide certificates of analysis (CoAs) with heavy metal panels conforming to EU or USP limits.

Microbial contamination: Mushroom-based adaptogens (reishi, lion's mane) processed under inadequate conditions may harbour excessive microbial loads. GMP-certified manufacturing and batch-specific microbial testing are essential.

Adulterants and fillers: Mycelium-on-grain products — common in the mushroom supplement sector — may contain 50–70% starch from the grain substrate, with correspondingly low concentrations of bioactive compounds. While not inherently dangerous, these products misrepresent their composition and deliver sub-therapeutic doses.

Pesticide residues: Non-organic botanicals may carry residues of agricultural pesticides, particularly for crops grown in regions with less stringent agricultural regulations. Organic certification or pesticide-panel testing adds a meaningful safety layer.

Reassurance with Boundaries

The honest safety message for adaptogens is reassuring but bounded. For healthy adults not taking the medications listed above, not pregnant or breastfeeding, and using quality-assured products at standard doses, the major adaptogens have demonstrated good safety profiles across clinical trials typically lasting 8–12 weeks. Ashwagandha and rhodiola in particular have accumulated substantial human safety data with no serious adverse events at recommended doses.

However, safety data beyond 12 weeks of continuous use is limited for most adaptogens. Long-term safety studies (6–12 months or longer) are rare in the botanical supplement literature. For B2B brands, recommending periodic cycling (e.g., 8 weeks on, 2 weeks off) is a pragmatic approach that aligns with the available evidence without overstating long-term safety confidence.

What This Means for the United Kingdom

UK regulatory bodies — the MHRA, FSA, and ASA — are increasingly focused on supplement safety communication. The MHRA has issued specific guidance on herbal product labelling, requiring clear contraindication warnings and interaction disclosures. Brands that fail to include adequate safety information on adaptogen products risk enforcement action, product recalls, and reputational damage. For B2B suppliers, providing pre-drafted safety panels, interaction summaries, and contraindication warnings as part of the ingredient supply package is becoming a baseline expectation rather than a value-added service. The suppliers who proactively address safety documentation will build stronger, more durable commercial relationships with UK brand customers.

Readers can learn more at Supplement Factory, the UK manufacturing partner behind many leading own-label and challenger brands.